Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/7/2013

SAN DIEGO, March 7, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and full year ended December 31, 2012.

For the fourth quarter of 2012, Cadence reported net product revenue from sales of OFIRMEV® (acetaminophen) injection of $17.1 million, nearly three times the amount reported for the fourth quarter of 2011. Additionally, during the fourth quarter of 2012, the company entered into an agreement to terminate its option to purchase Incline Therapeutics, Inc., in connection with the sale of Incline to a third party. As a result, Cadence received a payment of $13.1 million for the waiver of its option plus an additional $1.5 million for the shares of Incline stock held by the company in connection with the closing of the transaction in January 2013. Other recent highlights include the following:

  • Net product revenue for the fourth quarter of 2012 was $17.1 million, an increase of $3.2 million, or 23%, from the $13.9 million in net product revenue received during the third quarter of 2012.
  • Net product revenue for the twelve months ended December 31, 2012, was $50.1 million, more than four times the $11.5 million in net product revenue reported for 2011.
  • The company had over 3,750 unique customer accounts as of December 31, 2012, an increase of 8% from the third quarter of 2012, and 66% from the fourth quarter of 2011.
  • The average number of orders per customer increased more than 16% for the fourth quarter of 2012 as compared to the fourth quarter of 2011.  Further, the average order size during the same period increased approximately 40%.
  • The gross margin on sales of OFIR
    '/>"/>

  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
    2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
    3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
    4. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
    5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
    6. Cadence Pharmaceuticals to Host Analyst and Investor Day
    7. Cadence to Open Finished Medical Device Facility
    8. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
    9. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
    11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
    (Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
    (Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    (Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
    (Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
    (Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
    (Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
    (Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
    Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
    ... Prompts Extension of Promotion -, DENVER, July ... of functional foods, beverages and nutritional,supplements, announced that ... of the $1 million sales goal for the ... opportunity to earn,significant bonuses in July., John ...
    ... hardest hit states by this legislation, WASHINGTON, July ... significant funding cuts under legislation being,considered in Congress, according ... As Congress considers ways to halt the impending cut ... Medicare Advantage program to,pay for the fix. Legislation currently ...
    ... July 2 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, ... in the United States,District Court, Northern District of ... (Dornier) and NewStar Lasers,Inc. d/b/a CoolTouch, Inc. (CoolTouch)., ...
    ... ushers in The Art of Condoms (FDA-approved), as the ... latest hi-tech advancement in safe-sex., ... of designer-condoms. Remarkably shaped condoms,including the look-alike Dolphin Condom(TM) and ... designers could only dream,of making before. The Dolphin(TM) has all ...
    ... for environment, MELROSE PARK, Ill., July 2 ... that it has surpassed the,sale of 1 million green ... "We are seeing more and more people buying ... Jewel-Osco. "This is,likely due to the heightened awareness about ...
    ... disease can save some vision, experts say , , WEDNESDAY, ... to end in blindness, two new studies suggest. , ... for glaucoma has better outcomes than using glaucoma drainage ... end-stage glaucoma can be successfully treated. Both studies were ...
    Cached Medicine News:Health News:XELR8 Holdings Announces Continuation of 'XELR8 To A Million' Promotion 2Health News:Proposed Congressional Legislation Would Cut $784 Million From the Medicare Advantage Program in New York 2Health News:VNUS Medical Technologies, Inc. Files Patent Infringement Lawsuits Against Biolitec, Dornier and CoolTouch 2Health News:The New Condom That Breaks - - - the Mold. 2Health News:Jewel-Osco: 1 Million Reusable Shopping Bags Sold 2Health News:Glaucoma Treatment Can Prevent Blindness 2Health News:Glaucoma Treatment Can Prevent Blindness 3
    15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle....
    15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
    8 mm curved blade. Cutting edge on inside of curve. Flat handle....
    For use with N4096 R, N4097 R and N4098 R. 18 mm wide x 167 mm long. Ten per package. Designated most popular model or size....
    Medicine Products: